# Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS

> **NCT04615429** · PHASE2 · COMPLETED · sponsor: **Cristina Avendaño Solá** · enrollment: 20 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome
- COVID-19 Pneumonia

## Interventions

- **BIOLOGICAL:** Mesenchymal stromal cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04615429
- **Lead sponsor:** Cristina Avendaño Solá
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-15
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-02-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04615429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04615429, "Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04615429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*